Welcome to our dedicated page for Clover Health Investments news (Ticker: CLOV), a resource for investors and traders seeking the latest updates and insights on Clover Health Investments stock.
Clover Health Investments, Corp. reports developments in physician enablement technology and Medicare Advantage insurance. The company offers PPO and HMO Medicare Advantage plans and uses its Clover Assistant software platform to aggregate patient data, support clinical decision-making, and address chronic disease management for Medicare populations.
Recurring Clover Health news includes quarterly and annual results, Medicare Advantage membership trends, medical cost and profitability metrics, and guidance updates. Company updates also cover Counterpart Health, the subsidiary that extends the data-driven physician enablement platform beyond Clover’s Medicare Advantage plan, including interoperability collaborations, patient data access, and clinical research tied to conditions such as diabetes, chronic kidney disease, congestive heart failure, COPD, and preventive care.
Clover Health (NASDAQ:CLOV) has expressed strong support for the White House and CMS' initiative to improve healthcare data accessibility and interoperability. The company's AI platform, Counterpart Assistant, already integrates with most of the networks involved in CMS' Health Tech Ecosystem initiative.
The platform has demonstrated significant clinical outcomes, including 36 months earlier diagnosis and treatment of diabetes, 18% lower hospitalization rates for Congestive Heart Failure, and improved medication adherence. These results contributed to Clover Health PPO plans achieving a 4 Star rating for 2025, with an exceptional 4.94 out of 5 Stars on HEDIS measures.
The company's technology focuses on supporting independent clinicians in rural and underserved areas by providing unified access to patient data from various healthcare sources, enabling better care coordination and improved health outcomes.
Counterpart Health (NASDAQ:CLOV), a subsidiary of Clover Health, has appointed Vicky Bruner as Vice President of Operations. Bruner, formerly VP of Network Performance at Optum Care Network, will oversee critical functions including customer implementations, provider network engagement, and clinician onboarding.
In her previous role, Bruner led risk operations across five health plans in Washington and Oregon, focusing on quality performance and cost optimization for Medicare and Medicaid populations. At Counterpart, she will support the company's expansion initiatives and complex partnerships, leveraging her experience in provider enablement and value-based care models.
Clover Health (NASDAQ:CLOV) announced that CFO Peter Kuipers will present at the Canaccord Genuity 45th Annual Growth Conference on August 12, 2025, at 11:00 a.m. Eastern Time.
Investors can access both the live webcast and replay of the presentation through Clover Health's investor relations website at investors.cloverhealth.com.
Clover Health (NASDAQ:CLOV) has appointed Joseph Oldakowski as Vice President of Finance and Controller, reporting to CFO Peter Kuipers. Oldakowski brings nearly 20 years of healthcare and insurance finance experience, most recently serving as VP and Corporate Controller at Point32Health.
In his new role, Oldakowski will lead Clover's corporate accounting, GAAP, SEC, and statutory financial reporting and tax functions. His prior experience includes leadership positions at EmblemHealth, The Hartford, and MassMutual, along with public accounting experience at Melanson Heath specializing in healthcare audits.
The appointment strengthens Clover's financial leadership as the company focuses on scaling operations and driving profitable growth in its Medicare-focused healthcare business.
Clover Health (Nasdaq: CLOV) has announced a strategic partnership with IPC Digital Health to launch a new community pharmacy pilot program across New Jersey. The initiative leverages IPC's iCare+ Independent Pharmacy Network to help Medicare Advantage members better manage their medications and improve health outcomes.
The program integrates real-time monitoring tools powered by Clover Assistant data and AI models to track prescription fills, identify adherence gaps, and facilitate collaboration between local pharmacists, doctors, and Clover's care teams. This community-based approach aims to enhance medication management while keeping healthcare services local and personalized for seniors.
Clover Health (NASDAQ:CLOV) has scheduled its Second Quarter 2025 earnings release and conference call for August 5, 2025. The financial results will be released after market close, followed by a conference call and webcast at 5:00 p.m. Eastern Time.
Investors can access the conference call by dialing 800-245-3047 (U.S.) or 203-518-9765 (international) with conference ID CLOVQ225. A live and archived webcast will be available on the company's investor relations website for 12 months.
Clover Health (NASDAQ:CLOV) announced its upcoming inclusion in the broad-market Russell 3000® Index, effective June 30, 2025. This inclusion automatically grants the company membership in either the large-cap Russell 1000® Index or small-cap Russell 2000® Index, along with corresponding growth and value style indexes.
The Russell indexes reconstitution process captures the 4,000 largest US stocks based on total market capitalization as of April 30, 2025. According to FTSE Russell data, approximately $10.6 trillion in assets are benchmarked against Russell's US indexes as of June 2024.
Clover Health (NASDAQ: CLOV) subsidiary Counterpart Health released research showing positive outcomes associated with their AI-powered Counterpart Assistant (CA) technology in treating congestive heart failure patients. The study revealed that patients whose Primary Care Physicians use CA experienced 18% lower hospitalization rates and 25% lower 30-day readmission rates.
The technology provides actionable insights at point of care, supporting earlier disease detection and guideline-based treatment. Patients with CA-using physicians showed higher rates of outpatient cardiologist visits and in-home care management. This marks Counterpart's fourth retrospective analysis, following previous studies on Diabetes, Chronic Kidney Disease, and Medication Adherence.
Clover Health (Nasdaq: CLOV) announced significant changes to its Board of Directors. Lee A. Shapiro, current Chairman of the Audit Committee and Nominating and Corporate Governance Committee, will not seek re-election at the 2025 Annual Shareholders' Meeting, concluding his four-year tenure on June 10, 2025.
Shapiro's departure is due to his upcoming role as Chairman of the American Heart Association. Thomas L. Tran, a current Audit Committee member, will succeed Shapiro as Chairman of both the Audit Committee and the Nominating and Corporate Governance Committee effective June 10, 2025.
Both CEO Andrew Toy and Executive Chairperson Vivek Garipalli expressed gratitude for Shapiro's contributions and leadership during his tenure, while Tran committed to maintaining high standards of financial integrity and transparency in his new role.